GLP-RT
COA published
A synthetic triple receptor agonist peptide studied in in-vitro GIP, GLP-1 and glucagon receptor binding research.
From$79.00Select size
SEMA
An acylated GLP-1 receptor agonist analog studied in receptor-binding and peptide-stability research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 3
- Availability
- In stock
Select size
Quantity
1
Total
$54.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificate for this lot is pending. Every batch we ship is published at /coa before it goes out.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
Semaglutide is a GLP-1 analog developed at Novo Nordisk, and its structure is a case study in peptide half-life engineering. Native GLP-1 is cleared in about two minutes by dipeptidyl peptidase-4. Semaglutide carries three changes: an alpha-aminoisobutyric acid substitution at position 8 that blocks DPP-4 cleavage, a lysine substitution at position 34, and a C18 fatty diacid chain attached via a spacer at position 26 that binds serum albumin. Together these take a two-minute peptide to a roughly one-week circulating half-life. The discovery paper was published in the Journal of Medicinal Chemistry in 2015.
What has been characterised
Characterised as an agonist at the glucagon-like peptide-1 receptor (GLP-1R), a class-B G-protein-coupled receptor. The structural biology is well resolved: a 2021 Cell Reports study determined the structure and dynamics of semaglutide-bound GLP-1R–Gs complexes, showing directly how the analog engages the receptor. We describe this compound by receptor target and molecular structure only. Not FDA-approved in this form; the material supplied here is a research chemical and not a pharmaceutical product.
Sources
- 1.“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.” J Med Chem, 2015. PMID 26308095
- 2.“Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.” Cell Rep, 2021. PMID 34260945
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
GLP-TRZ
COA published
A dual GIP/GLP-1 receptor agonist peptide studied in comparative receptor-affinity research.
From$105.00Select size
AOD-9604
COA published
A modified C-terminal fragment of human growth hormone (176-191) studied in structural and receptor research.
$49.00Notify me
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.